PDF(Pubmed)
Abstract：
UNASSIGNED: Device closure of a patent ductus arteriosus (PDA) is rapidly evolving, with the Amplatzer Piccolo Occluder (Abbott) receiving US Food and Drug Administration approval and becoming the first device approved for PDA closure in patients ≥700 g. We report on the first known cases of complete left pulmonary artery (LPA) occlusion following Piccolo closure of a PDA in premature infants.
UNASSIGNED: Retrospective chart analysis of PDA closures.
UNASSIGNED: We have performed over 50 cases of Piccolo device closure of the PDA in preterm neonates in the past 2 years, with these 2 cases representing our only complications (4%). This represents a total complication rate similar to or lower than most centers that have published data for this procedure.
UNASSIGNED: Although rare, severe LPA obstruction can be seen in premature infants following device closure of the PDA. The Piccolo device is designed to ideally remain entirely intraductal. Although our device selection appeared to provide a device short enough for the given ductal length, we recommend, whenever possible, giving consideration to using the shortest possible device. We also recommend increasing the frequency of echocardiographic surveillance to weekly studies if at any time the imaging demonstrates an increase in the degree of obstruction/turbulence.
UNASSIGNED: Retrospective chart analysis of PDA closures.
UNASSIGNED: We have performed over 50 cases of Piccolo device closure of the PDA in preterm neonates in the past 2 years, with these 2 cases representing our only complications (4%). This represents a total complication rate similar to or lower than most centers that have published data for this procedure.
UNASSIGNED: Although rare, severe LPA obstruction can be seen in premature infants following device closure of the PDA. The Piccolo device is designed to ideally remain entirely intraductal. Although our device selection appeared to provide a device short enough for the given ductal length, we recommend, whenever possible, giving consideration to using the shortest possible device. We also recommend increasing the frequency of echocardiographic surveillance to weekly studies if at any time the imaging demonstrates an increase in the degree of obstruction/turbulence.
摘要：
■动脉导管未闭（PDA）的封堵器正在迅速发展，AmplatzerPiccolo封堵器（Abbott）获得美国食品和药物管理局的批准，并成为首个被批准用于≥700g患者的PDA封堵的装置。我们报告了早产儿在Piccolo封堵PDA后出现的首例完全左肺动脉（LPA）封堵的已知病例。
■PDA关闭的回顾性图表分析。
■在过去2年中，我们在早产新生儿中进行了50多例Piccolo装置封堵PDA，这2例代表我们唯一的并发症(4%)。这表示总并发症发生率与已发布此手术数据的大多数中心相似或更低。
■虽然罕见，在PDA封堵装置后,早产儿出现严重的LPA梗阻.Piccolo装置被设计为理想地完全保持在导管内。虽然我们的设备选择似乎提供了一个足够短的设备，对于给定的导管长度，我们建议,只要有可能,考虑使用尽可能短的设备。如果在任何时候影像学显示阻塞/湍流程度增加，我们还建议将超声心动图监测的频率增加到每周研究。
■PDA关闭的回顾性图表分析。
■在过去2年中，我们在早产新生儿中进行了50多例Piccolo装置封堵PDA，这2例代表我们唯一的并发症(4%)。这表示总并发症发生率与已发布此手术数据的大多数中心相似或更低。
■虽然罕见，在PDA封堵装置后,早产儿出现严重的LPA梗阻.Piccolo装置被设计为理想地完全保持在导管内。虽然我们的设备选择似乎提供了一个足够短的设备，对于给定的导管长度，我们建议,只要有可能,考虑使用尽可能短的设备。如果在任何时候影像学显示阻塞/湍流程度增加，我们还建议将超声心动图监测的频率增加到每周研究。
